Network reinforcement driven drug repurposing for COVID-19 by exploiting disease-gene-drug associations
Authors:
Yonghyun Nam,
Jae-Seung Yun,
Seung Mi Lee,
Ji Won Park,
Ziqi Chen,
Brian Lee,
Anurag Verma,
Xia Ning,
Li Shen,
Dokyoon Kim
Abstract:
Currently, the number of patients with COVID-19 has significantly increased. Thus, there is an urgent need for developing treatments for COVID-19. Drug repurposing, which is the process of reusing already-approved drugs for new medical conditions, can be a good way to solve this problem quickly and broadly. Many clinical trials for COVID-19 patients using treatments for other diseases have already…
▽ More
Currently, the number of patients with COVID-19 has significantly increased. Thus, there is an urgent need for developing treatments for COVID-19. Drug repurposing, which is the process of reusing already-approved drugs for new medical conditions, can be a good way to solve this problem quickly and broadly. Many clinical trials for COVID-19 patients using treatments for other diseases have already been in place or will be performed at clinical sites in the near future. Additionally, patients with comorbidities such as diabetes mellitus, obesity, liver cirrhosis, kidney diseases, hypertension, and asthma are at higher risk for severe illness from COVID-19. Thus, the relationship of comorbidity disease with COVID-19 may help to find repurposable drugs. To reduce trial and error in finding treatments for COVID-19, we propose building a network-based drug repurposing framework to prioritize repurposable drugs. First, we utilized knowledge of COVID-19 to construct a disease-gene-drug network (DGDr-Net) representing a COVID-19-centric interactome with components for diseases, genes, and drugs. DGDr-Net consisted of 592 diseases, 26,681 human genes and 2,173 drugs, and medical information for 18 common comorbidities. The DGDr-Net recommended candidate repurposable drugs for COVID-19 through network reinforcement driven scoring algorithms. The scoring algorithms determined the priority of recommendations by utilizing graph-based semi-supervised learning. From the predicted scores, we recommended 30 drugs, including dexamethasone, resveratrol, methotrexate, indomethacin, quercetin, etc., as repurposable drugs for COVID-19, and the results were verified with drugs that have been under clinical trials. The list of drugs via a data-driven computational approach could help reduce trial-and-error in finding treatment for COVID-19.
△ Less
Submitted 12 August, 2020;
originally announced August 2020.
Determination of carbohydrates in infant milk powders by ultra-performance liquid chromatography with evaporative light scattering detector and BEH HILIC column
Authors:
Hyon-Hui Ri,
Yong-A Choe,
Jong-Ho Yun,
Kye-Ryong Sin
Abstract:
The possibility of carbohydrate separation in BEH HILIC (Ethylene Bridged Hybride, Hydrophilic Interaction Liquid Chromatography) column was studied by ultra-performance liquid chromatography (UPLC) with evaporative light scattering detector (ELSD) and mobile phase containing amine compounds as modifiers. The chromatography conditions and ELSD parameters were optimized to separate five typical car…
▽ More
The possibility of carbohydrate separation in BEH HILIC (Ethylene Bridged Hybride, Hydrophilic Interaction Liquid Chromatography) column was studied by ultra-performance liquid chromatography (UPLC) with evaporative light scattering detector (ELSD) and mobile phase containing amine compounds as modifiers. The chromatography conditions and ELSD parameters were optimized to separate five typical carbohydrates and applied to analysis of four infant milk powders. The linear ranges of carbohydrate determination were 20-300mg/L for fructose and glucose, 20-250mg/L for sucrose and lactose, and 35-180mg/L for fructo-oligosaccharide. The LODs were 16.4mg/L for fructose and glucose, 17.3mg/L for sucrose, 20.0mg/L for lactose, and 46.7mg/L for fructo-oligosaccharide. Relative standard deviations (RSDs) ranged between 3.45-4.23%, 1.46-4.17%, 4.14-5.60%, 1.39-4.09%, and 2.49-3.61% for fructose, glucose, sucrose, lactose, and fructo-oilgosaccharide, respectively and recoveries ranged between 95.0 and 105.4%
△ Less
Submitted 20 November, 2017;
originally announced November 2017.
